Acute myeloid leukemia treatment Xospata can be prescribed at general hospitals. According to related industries, Xospata (Gilteritinib), a drug for acute myeloid leukemia (AML) of Astellas Korea, has passed the drug committee (DC) of SNUH and SMC, and is also in progress at other major hospitals nationwide.

This drug has already been prescribed in the U.S. and Japan since 2018, obtained European EMA approval last month, and was approved as an orphan drug in Korea in March last year.

The effectiveness of Xospata has been demonstrated in a phase 3 clinical ADMIRAL study. In the ADMIRAL test, overall survival (OS) was 5.6 months in other chemotherapy groups, compared to 9.3 months in Xospa